{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:16:24Z","timestamp":1789200984432,"version":"build-2803163510"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.pharep.2017.12.003","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T13:15:53Z","timestamp":1513343753000},"page":"533-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The impact of antipsychotics as a risk factor for thromboembolism"],"prefix":"10.1007","volume":"70","author":[{"given":"Ewa A.","family":"Og\u0142odek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek J.","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna D.","family":"Grzesi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Araszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Szromek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"8","key":"10.1016\/j.pharep.2017.12.003_bib0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharep.2017.12.003_bib0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-244X-8-84","article-title":"Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis","volume":"8","author":"Osborn","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharep.2017.12.003_bib0015","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eurpsy.2016.02.004","article-title":"Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders","volume":"35","author":"P\u00e9rez-Pi\u00f1ar","year":"2016","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pharep.2017.12.003_bib0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease \u2013 a non-systematic review of epidemiology, possible causes, and interventions","volume":"5","author":"Ringen","year":"2014","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","article-title":"Epidemiology and risk factors for venous thrombosis","volume":"44","author":"Cushman","year":"2007","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.pharep.2017.12.003_bib0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.eurpsy.2005.07.008","article-title":"Cigarette smoking in long-term schizophrenia","volume":"21","author":"Salokangas","year":"2006","journal-title":"Eur Psychiatry"},{"issue":"11\u201312","key":"10.1016\/j.pharep.2017.12.003_bib0035","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2298\/SARH1512712P","article-title":"Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome","volume":"143","author":"Popovi\u0107","year":"2015","journal-title":"Srp Arh Celok Lek"},{"key":"10.1016\/j.pharep.2017.12.003_bib0040","doi-asserted-by":"crossref","first-page":"c4245","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study","volume":"341","author":"Parker","year":"2010","journal-title":"BMJ"},{"issue":"9210","key":"10.1016\/j.pharep.2017.12.003_bib0045","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(00)02066-3","article-title":"Association of venous thromboembolism and clozapine","volume":"355","author":"H\u00e4gg","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JCP.0b013e318285683b","article-title":"Fatal multisystem venous thrombosis associated with clozapine","volume":"33","author":"Hu","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jemermed.2003.12.027","article-title":"Massive pulmonary embolism in a young patient on clozapine therapy","volume":"27","author":"Yang","year":"2004","journal-title":"J Emerg Med"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1176\/appi.neuropsych.12040077","article-title":"Pulmonary thromboembolism associated with clozapine","volume":"25","author":"Chate","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.pharep.2017.12.003_bib0070","doi-asserted-by":"crossref","first-page":"703218","DOI":"10.1155\/2015\/703218","article-title":"Clozapine-induced late agranulocytosis and severe neutropenia complicated with streptococcus pneumonia, venous thromboembolism, and allergic vasculitis in treatment-resistant female psychosis","volume":"2015","author":"Voulgari","year":"2015","journal-title":"Case Rep Med"},{"issue":"9","key":"10.1016\/j.pharep.2017.12.003_bib0075","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1345\/aph.1E021","article-title":"Fatal venous thromboembolism associated with antipsychotic therapy","volume":"38","author":"Farah","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.pharep.2017.12.003_bib0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/jnp.2009.21.3.343a","article-title":"Cerebral venous sinus thrombosis may be associated with clozapine","volume":"21","author":"Werring","year":"2009","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"3","key":"10.1016\/j.pharep.2017.12.003_bib0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1176\/appi.neuropsych.12070186","article-title":"Clozapine-induced recurrent pulmonary thromboembolism","volume":"25","author":"Munoli","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"April","key":"10.1016\/j.pharep.2017.12.003_bib0090","article-title":"A case report of clozapine continuation after pulmonary embolism in the context of other risk factors for thromboembolism","author":"Goh","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"issue":"5","key":"10.1016\/j.pharep.2017.12.003_bib0095","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4088\/JCP.v64n0518a","article-title":"Clozapine and venous thromboembolism: further evidence","volume":"64","author":"Selten","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0100","first-page":"175","article-title":"Thrombotic complications of treatment with antipsychotic drugs","volume":"104","author":"Shulman","year":"2013","journal-title":"Minerva Med"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jemermed.2007.07.074","article-title":"Pulmonary thromboembolism associated with olanzapine and risperidone","volume":"35","author":"Borras","year":"2008","journal-title":"J Emerg Med"},{"issue":"7","key":"10.1016\/j.pharep.2017.12.003_bib0110","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4088\/JCP.v68n0711","article-title":"Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey","volume":"68","author":"Suvisaari","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0115","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease","volume":"150","author":"Hennekens","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharep.2017.12.003_bib0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1757-1626-3-36","article-title":"Olanzapine and pulmonary embolism, a rare association: a case report","volume":"3","author":"Maempel","year":"2010","journal-title":"Cases J"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1440-1819.2008.01899.x","article-title":"Four cases of venous thromboembolism associated with olanzapine","volume":"63","author":"Maly","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"10.1016\/j.pharep.2017.12.003_bib0130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/0366-6999.150124","article-title":"Pulmonary thromboembolism associated with olanzapine treatment","volume":"128","author":"Wang","year":"2015","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0135","first-page":"186","article-title":"Massive pulmonary emboli associated with olanzapine","volume":"101","author":"Hilli","year":"2008","journal-title":"Ir Med J"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.thromres.2012.10.002","article-title":"Incidence of venous thromboembolism in psychiatric units","volume":"130","author":"Delluc","year":"2012","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjopharm.2011.03.004","article-title":"Risk of serious cardiac events in older adults using antipsychotic agents","volume":"9","author":"Mehta","year":"2011","journal-title":"Am J Geriatr Pharmacother"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0150","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/JCP.0b013e3182a412d5","article-title":"Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia","volume":"33","author":"Schmedt","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.pharep.2017.12.003_bib0155","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JCP.0b013e3181f0e87d","article-title":"Antipsychotic drug use and the risk of venous thromboembolism in elderly patients","volume":"30","author":"Kleijer","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.pharep.2017.12.003_bib0160","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/14740330903117271","article-title":"Associations between venous thromboembolism and antipsychotics: a study of the WHO database of adverse drug reactions","volume":"8","author":"H\u00e4gg","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"10.1016\/j.pharep.2017.12.003_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2013.12.038","article-title":"Pulmonary thromboembolism due to paliperidone: report of 2 cases","volume":"32","author":"\u015eeng\u00fcl","year":"2014","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.pharep.2017.12.003_bib0170","first-page":"718950","article-title":"Pulmonary embolism related to amisulpride treatment: a case report","volume":"2013","author":"Skokou","year":"2013","journal-title":"Case Rep Psychiatry"},{"issue":"9","key":"10.1016\/j.pharep.2017.12.003_bib0175","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1253\/circj.68.850","article-title":"Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics","volume":"68","author":"Hamanaka","year":"2004","journal-title":"Circ J"},{"issue":"22","key":"10.1016\/j.pharep.2017.12.003_bib0180","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1001\/archinte.165.22.2677","article-title":"Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9237","key":"10.1016\/j.pharep.2017.12.003_bib0185","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(00)02784-7","article-title":"Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case control study","volume":"356","author":"Zornberg","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/pds.2210","article-title":"Antipsychotic drugs and risk of pulmonary embolism","volume":"21","author":"Allenet","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1819.2007.01773.x","article-title":"Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients","volume":"62","author":"Mal\u00fd","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0200","first-page":"18","article-title":"Elevated rest heart rate in psychiatric patients and different effects of psychotropic medication","volume":"49","author":"Sarlon","year":"2016","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.pharep.2017.12.003_bib0205","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1440-1681.2007.04650.x","article-title":"In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation","volume":"34","author":"Axelsson","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0210","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jpsychires.2008.09.009","article-title":"Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients","volume":"43","author":"Shen","year":"2009","journal-title":"J Psychiatr Res"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0215","doi-asserted-by":"crossref","first-page":"398","DOI":"10.12669\/pjms.312.6049","article-title":"Study on relationships among deep vein thrombosis, homocysteine & related B group vitamins","volume":"31","author":"Ekim","year":"2015","journal-title":"Pak J Med Sci"},{"issue":"3","key":"10.1016\/j.pharep.2017.12.003_bib0220","first-page":"499","article-title":"Levels of prolactin in relation to coagulation factors and risk of venous thrombosis: results of a large population-based case-control study (MEGA-study)","volume":"108","author":"Stuijver","year":"2012","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.pharep.2017.12.003_bib0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-0031-1280814","article-title":"Antipsychotics and venous thromboembolism risk: a meta-analysis","volume":"44","author":"Zhang","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12154-009-0018-6","article-title":"In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner","volume":"2","author":"Oruch","year":"2009","journal-title":"J Chem Biol"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/YIC.0b013e32833643fd","article-title":"Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients","volume":"25","author":"L\u00f6ffler","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2017.12.003_bib0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2008.03.004","article-title":"Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives","volume":"103","author":"Carrizo","year":"2008","journal-title":"Schizophr Res"},{"issue":"11","key":"10.1016\/j.pharep.2017.12.003_bib0245","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-2006-955090","article-title":"Increased prolactin in acute coronary syndromes as putative Co-activator of ADP-stimulated P-selectin expression","volume":"38","author":"Raaz","year":"2006","journal-title":"Horm Metab Res"},{"issue":"9","key":"10.1016\/j.pharep.2017.12.003_bib0250","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0006-3223(02)01400-2","article-title":"Elevated expression of integrin alpha(IIb) beta(IIIa) in drug-na\u00efve, first-episode schizophrenic patients","volume":"52","author":"Walsh","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0255","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40264-013-0127-6","article-title":"Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational","volume":"37","author":"Barbui","year":"2014","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.pharep.2017.12.003_bib0260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.psychres.2010.04.049","article-title":"Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia","volume":"187","author":"Chang","year":"2011","journal-title":"Psychiatry Res"},{"issue":"5","key":"10.1016\/j.pharep.2017.12.003_bib0265","doi-asserted-by":"crossref","first-page":"769","DOI":"10.4088\/JCP.08l04572","article-title":"Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone","volume":"70","author":"Schwartz","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01541177","article-title":"Anticardiolipin antibodies are elevated in drug-free, multiply affect families with schizophrenia","volume":"14","author":"Firer","year":"1994","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0275","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.psychres.2008.05.011","article-title":"Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication","volume":"169","author":"Halacheva","year":"2009","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0280","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.psychres.2008.05.011","article-title":"Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication","volume":"169","author":"Halacheva","year":"2009","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0285","first-page":"61","article-title":"Thrombosis and psychosis\u2013possible association with the antiphospholipid syndrome and anticardiolipin antibodies","volume":"102","author":"Mulligan","year":"2009","journal-title":"Ir Med J"},{"key":"10.1016\/j.pharep.2017.12.003_bib0290","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.thromres.2016.03.024","article-title":"Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis","volume":"141","author":"Ventura","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharep.2017.12.003_bib0295","first-page":"1","article-title":"Venous thromboembolism during treatment with antipsychotics \u2013 results of a drug surveillance program","volume":"23","author":"Letmaier","year":"2017","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0300","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5692\/clinicalneurol.cn-000819","article-title":"Cerebral venous sinus thrombosis associated with cysteinemia due to combined deficiencies of folate and vitamin B12","volume":"56","author":"Kanaya","year":"2016","journal-title":"Rinsho Shinkeigaku"},{"issue":"5","key":"10.1016\/j.pharep.2017.12.003_bib0305","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/08039488.2012.745601","article-title":"Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia","volume":"67","author":"Vuksan-Cusa","year":"2013","journal-title":"Nord J Psychiatry"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0310","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1017\/neu.2015.30","article-title":"Homocysteine levels in schizophrenia patients newly admitted to an acute psychiatric ward","volume":"27","author":"Di Lorenzo","year":"2015","journal-title":"Acta Neuropsychiatr"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0315","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.schres.2014.07.033","article-title":"Serum levels of BDNF, folate and homocysteine: in relation to hippocampal volume and psychopathology in drug na\u00efve, first episode schizophrenia","volume":"159","author":"Song","year":"2014","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000437098","article-title":"Homocysteine-induced endothelial dysfunction","volume":"67","author":"Lai","year":"2015","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.pharep.2017.12.003_bib0325","first-page":"477","article-title":"Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers","volume":"11","author":"Ishioka","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"10.1016\/j.pharep.2017.12.003_bib0330","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotics","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharep.2017.12.003_bib0335","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-244X-11-2","article-title":"Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study","volume":"11","author":"Masopust","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharep.2017.12.003_bib0340","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CLEP.S4969","article-title":"Antipsychotics and risk of venous thromboembolism: a population-based case-control study","volume":"1","author":"J\u00f6nsson","year":"2009","journal-title":"Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.pharep.2017.12.003_bib0345","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4306\/pi.2015.12.4.566","article-title":"One-year follow up of serum prolactin level in schizophrenia patients treated with blonaserin: a case series","volume":"12","author":"Takahashi","year":"2015","journal-title":"Psychiatry Investig"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0350","first-page":"1093","article-title":"The comparison of immobilization with isolation","volume":"39","author":"Sidorowicz","year":"2005","journal-title":"Psychiatr Pol"},{"issue":"4","key":"10.1016\/j.pharep.2017.12.003_bib0355","first-page":"417","article-title":"Resource document on the use of restraint and seclusion in correctional mental health care","volume":"35","author":"Metzner","year":"2007","journal-title":"J Am Acad Psychiatry Law"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0360","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.encep.2012.06.007","article-title":"Specific treatments of the psychiatric community and thrombogenesis","volume":"39","author":"Khammassi","year":"2013","journal-title":"Encephale"},{"issue":"10","key":"10.1016\/j.pharep.2017.12.003_bib0365","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2298\/VSP1310903S","article-title":"Fatal pulmonary thromboembolism after prolonged physical immobilization in hospitalized psychiatric patients","volume":"70","author":"Stefanovi\u0107","year":"2013","journal-title":"Vojnosanit Pregl"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0370","first-page":"1","article-title":"Management of venous thromboembolism in psychiatric patients","volume":"90","author":"Khammassi","year":"2012","journal-title":"Tunis Med"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0375","first-page":"20","article-title":"Risk factor assessment and counselling for 12 months reduces metabolic and cardiovascular risk in overweight or obese patients with schizophrenia spectrum disorders: the CRESSOB study","volume":"44","author":"Guti\u00e9rrez-Rojas","year":"2016","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/j.pharep.2017.12.003_bib0380","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.psychres.2016.04.105","article-title":"Incidence of deep vein thrombosis in catatonic patients: a chart review","volume":"241","author":"Ishida","year":"2016","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0385","first-page":"175","article-title":"Thrombotic complications of treatment with antipsychotic drugs","volume":"104","author":"Shulman","year":"2013","journal-title":"Minerva Med"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0390","doi-asserted-by":"crossref","DOI":"10.1136\/bmjquality.u205852.w3226","article-title":"Introduction of a venous thromboembolism prophylaxis protocol for older adult psychiatric patients","volume":"4","author":"Croxford","year":"2015","journal-title":"BMJ Qual Improv Rep"},{"issue":"9237","key":"10.1016\/j.pharep.2017.12.003_bib0395","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(00)02784-7","article-title":"Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study","volume":"356","author":"Zornberg","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharep.2017.12.003_bib0400","doi-asserted-by":"crossref","first-page":"c4245","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study","volume":"341","author":"Parker","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.pharep.2017.12.003_bib0405","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.genhosppsych.2014.06.007","article-title":"Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review","volume":"36","author":"Ishida","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"10.1016\/j.pharep.2017.12.003_bib0410","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.13027","article-title":"Excellence, quality and limitations of the NICE venous thromboembolism score tool: how can it be improved?","volume":"167","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.pharep.2017.12.003_bib0415","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.psym.2013.04.001","article-title":"Incidence of deep vein thrombosis in restrained psychiatric patients","volume":"55","author":"Ishida","year":"2014","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.pharep.2017.12.003_bib0420","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.encep.2015.05.004","article-title":"Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients","volume":"42","author":"Jalenques","year":"2016","journal-title":"Encephale"},{"issue":"4","key":"10.1016\/j.pharep.2017.12.003_bib0425","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/15672026113109990025","article-title":"Prolactin and blood-brain barrier permeability","volume":"10","author":"Rosas-Hernandez","year":"2013","journal-title":"Curr Neurovasc Res"},{"issue":"8","key":"10.1016\/j.pharep.2017.12.003_bib0430","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00002018-200831080-00005","article-title":"Associations between venous thromboembolism and antipsychotics: a study of the WHO database of adverse drug reactions","volume":"31","author":"H\u00e4gg","year":"2008","journal-title":"Drug Saf"},{"issue":"9896","key":"10.1016\/j.pharep.2017.12.003_bib0435","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharep.2017.12.003_bib0440","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.jcp.0000088914.24613.51","article-title":"Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study","volume":"23","author":"Wallaschofski","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.pharep.2017.12.003_bib0445","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1176\/appi.ajp.159.10.1790","article-title":"Elevated homocysteine levels in young male patients with schizophrenia","volume":"159","author":"Levine","year":"2002","journal-title":"Am J Psychiatry"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016302055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016302055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:28Z","timestamp":1752611848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2017.12.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1734114016302055"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2017.12.003","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of antipsychotics as a risk factor for thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2017.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}